CAPTRUST Financial Advisors
KYMR icon

CAPTRUST Financial Advisors’s Kymera Therapeutics KYMR Stock Holding History

CAPTRUST Financial Advisors’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$325K Buy
+2,833
New +$243K ﹤0.01% 2525
2022
Q3 		– Sell
-134
Closed -$3K – 3136
2022
Q2 		$3K Sell
134
-2
-1% -$47 ﹤0.01% 4307
2022
Q1 		$6K Buy
+136
New +$5.74K ﹤0.01% 4076
2021
Q2 		– Sell
-7
Closed – – 4587
2021
Q1 		$0 Buy
+7
New +$421 ﹤0.01% 4422

Other funds holding KYMR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

CAPTRUST Financial Advisors's KYMR Position: Q2 2026 in Review

CAPTRUST Financial Advisors opened a new position in Kymera Therapeutics (KYMR) in Q2 2026: 2,833 shares worth $325K. The stake represents ﹤0.01% of the portfolio and ranks #2525 among its holdings. This is a return to the name: CAPTRUST Financial Advisors previously reported a position in KYMR as recently as Q2 2022.

CAPTRUST Financial Advisors first reported a position in KYMR in Q1 2021 and has held it in 4 quarters since. 277 funds tracked by Wall St. Rank hold KYMR as of Q2 2026.

  • CAPTRUST Financial Advisors held 2,833 shares of Kymera Therapeutics worth $325K as of Q2 2026.
  • Kymera Therapeutics was a new CAPTRUST Financial Advisors position in Q2 2026.
  • Kymera Therapeutics made up ﹤0.01% of CAPTRUST Financial Advisors's portfolio in Q2 2026, its #2525 holding.
  • CAPTRUST Financial Advisors first reported a position in Kymera Therapeutics in Q1 2021 and has held it in 4 quarters since.
  • 277 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q2 2026.

Based on CAPTRUST Financial Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.